Inactief instrument

Andere talen Nanoantibiotics Inc Other OTC

Aandelen

US63009U1025

slotkoers Other OTC Andere beurzen
- ^USD	-

29/04	BioVie krijgt tot $13,1 miljoen van het Amerikaanse Ministerie van Defensie om bezisterim te evalueren voor langdurige COVID	MT
29/04	BioVie krijgt tot $13,1 miljoen financiering van het Amerikaanse Ministerie van Defensie om Bezisterim (NE3107) te evalueren voor de behandeling van Long COVID	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID	29/04
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID	29/04
BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim for the Treatment of Long COVID	29/04
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints	25/04
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation	18/04
Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation	26/03
Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioVie Inc. of Class Action Lawsuit and Upcoming Deadlines - BIVI	19/03
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)	18/03
Shareholders that lost money on BioVie Inc.(BIVI) should contact Levi & Korsinsky about pending Class Action - BIVI	15/03
The Gross Law Firm Notifies Shareholders of BioVie Inc. (BIVI) of a Class Action Lawsuit and an Upcoming Deadline	14/03
BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit	13/03
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie	13/03
BIVI DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI	13/03
BIOVIE INC. CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by March 19, 2024	12/03
Class Action Filed Against BioVie Inc. (BIVI) - March 19, 2024 Deadline to Join - Contact Levi & Korsinsky	12/03
BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities	11/03
BioVie Announces Pipeline Update and Near-Term Clinical Priorities	11/03
BioVie Inc. Class Action: The Gross Law Firm Reminds BioVie Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 19, 2024 - BIVI	11/03
ROSEN, LEADING INVESTOR COUNSEL, Encourages BioVie Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - BIVI	10/03
BIVI Investors Have Opportunity to Lead BioVie Inc. Securities Fraud Lawsuit	08/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nanoantibiotics Inc Other OTC

Aandelen

US63009U1025

Andere talen

Filters